SEC Company Response from NOVARTIS AG (NVS, NVSEF) (CIK 0001114448) (NVS) — Mar 27, 2017
NOVARTIS AG (NVS, NVSEF) (CIK 0001114448)
Date: March 27, 2017 · CIK: 0001114448 · Accession: 0001104659-17-019314
AI Filing Summary & Sentiment
Letter
Office of Healthcare and Insurance Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2016 Filed January 25, 2017 File No. 1-15024
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Harry Kirsch, our Chief Financial Officer, dated March 23, 2017. As agreed in a recent telephone call between Barry Rosenfeld, of our affiliate Novartis Finance Corporation, and Mary Mast, Senior Staff Accountant at SEC, we will respond to your letter on or before April 20, 2017.
Respectfully submitted,
Novartis AG
Show Raw Text
CORRESP 1 filename1.htm Novartis AG Postfach 4002 Basel Switzerland March 27, 2017 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Office of Healthcare and Insurance US Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2016 Filed January 25, 2017 File No. 1-15024 Dear Mr. Rosenberg: We are in receipt of your letter addressed to Harry Kirsch, our Chief Financial Officer, dated March 23, 2017. As agreed in a recent telephone call between Barry Rosenfeld, of our affiliate Novartis Finance Corporation, and Mary Mast, Senior Staff Accountant at SEC, we will respond to your letter on or before April 20, 2017. Respectfully submitted, Novartis AG /s/ HARRY KIRSCH /s/ FELIX R. EHRAT Harry Kirsch Felix R. Ehrat Chief Financial Officer General Counsel Novartis Group Novartis Group